{"entity":{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","aka":["ImmunoVaccine Technologies, Inc.","ImmunoVaccine Technologies","IMV Inc.","IMV Inc","Immunovaccine Technologies Inc."],"tldr":"Immunovaccine (IMV) is a Canadian biotechnology company founded in 2000 in Halifax, Nova Scotia, whose survivin-targeted immunotherapy DPX-Survivac is tested with pembrolizumab and low-dose cyclophosphamide in two OnCo trials, in relapsed diffuse large B-cell lymphoma and in selected solid tumours.","summary":"Immunovaccine is a company based in Halifax, Canada, founded in 2000 (Wikidata Q30282846, which also gives its website; a second Wikidata item, Q140169711, places Immunovaccine Technologies Inc. in Dartmouth). ClinicalTrials.gov registers it as ImmunoVaccine Technologies, Inc. (IMV Inc.), an industry sponsor, with Merck Sharp & Dohme as collaborator. It leads two phase 2 trials recorded in OnCo: NCT04920617 (VITALIZE, DPX-Survivac and pembrolizumab with and without intermittent low-dose cyclophosphamide in relapsed or refractory DLBCL) and NCT03836352 (the same combination in selected advanced and recurrent solid tumours, recorded under ovarian, hepatocellular, non-small-cell and small-cell lung cancer). DPX-Survivac is its own product, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Official website","url":"http://www.imvaccine.com/"},{"label":"Wikidata Q30282846","url":"https://www.wikidata.org/wiki/Q30282846"},{"label":"ClinicalTrials.gov: trials led by ImmunoVaccine Technologies, Inc.","url":"https://clinicaltrials.gov/search?lead=ImmunoVaccine%20Technologies%2C%20Inc."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["dlbcl","ovarian","hcc","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","cyclophosphamide"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04920617","nct03836352"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Halifax, Nova Scotia","country":"CA","companyType":"biotech","website":"http://www.imvaccine.com/","founded":2000,"investors":[],"funding":[]},"route":"/companies/immunovaccine/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct04920617","kind":"trial","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","route":"/trials/nct04920617/"},{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/"}]}}